Publication Date:
2016-12-02
Description:
Background: There is a well-known risk of developing multiple myeloma in plasmacytoma, especially in solitary bone tumors. However, the risk of other cancers is not clear. The aim of this study was to estimate the risk of second cancers in patients with plasmacytoma, as compared to general population, and patients with multiple myeloma. Methods: Surveillance, Epidemiology and End results (SEER) 18 dataset was queried to identify patients (age Results : With a follow-up of 13,392 person-years, 331-second cancers were diagnosed in 2046 plasmacytoma survivors (1155 SPB and 891 extraosseous plasmacytoma). The risk of subsequent solid tumors was not higher compared to age and sex matched background population with a SIR of 1.02 (95 % CI .88-1.17 AER 2.23/10,000). The risk was higher for developing multiple myeloma (SIR 30.8 25-38 AER 67/10,000), leukemia (SIR 3.4, 95% CI; 2-5.2 AER 10/10,000) and non-Hodgkin's lymphoma (NHL) (SIR 3.2, 95 % CI 2.1-4.7 AER 13.4/10,000) in "two-month" survivors of plasmacytoma as compared to general population. The risk of developing solid tumors was similar in SPB (SIR 1.07, 95% CI; .87-1.30 AER 9/10,000) and extraosseous (SIR .98, 95% CI; .77-1.19 AER -5/10,000) plasmacytoma. However the risk of transformation to multiple myeloma was 3.7 fold (hazard ratio 3.7, 95% CI; 2.2-6.3) (p
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink